<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006115</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068128</org_study_id>
    <secondary_id>FRE-GERCOR-C98-3-FIREFOX</secondary_id>
    <secondary_id>EU-20023</secondary_id>
    <nct_id>NCT00006115</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>Alternation of FOLFOX6 (Oxaliplatin - Leucovorin - Fluorouracil) and FOLFIRI (Irinotecan - Leucovorin - Fluorouracil) as Second Line Treatment of Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating
      patients who have metastatic colorectal cancer that has not responded to previous
      chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the efficacy of oxaliplatin, leucovorin calcium, and fluorouracil
      followed by irinotecan, leucovorin calcium, and fluorouracil in terms of progression free
      survival in patients with metastatic colorectal cancer. II. Evaluate these treatment regimens
      in terms of overall survival, response rate, toxicity, and quality of life in this patient
      population.

      OUTLINE: This is a multicenter study. Patients receive 4 courses of oxaliplatin IV and
      leucovorin calcium IV over 2 hours on day 1 followed by fluorouracil IV continuously over 46
      hours. Following the initial 4 courses of therapy, patients receive 4 courses of irinotecan
      IV over 30-90 minutes and leucovorin calcium IV over 2 hours on day 1 followed by
      fluorouracil IV continuously over 46 hours. Courses repeat every 2 weeks in the absence of
      disease progression or unacceptable toxicity. Quality of life is assessed every 8 weeks.
      Patients are followed every 3 months until death.

      PROJECTED ACCRUAL: A total of 14-39 patients will be accrued for this study over 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 1999</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed metastatic adenocarcinoma of the colon or
        rectum Measurable or evaluable lesion or residual disease (e.g., ascites, bone metastases)
        Failure after first line therapy Fluorouracil and leucovorin calcium OR Raltitrexed No
        oxaliplatin or irinotecan Relapse within 6 months of adjuvant therapy Relapse within 6
        months of hepatic artery infusion chemotherapy for resected hepatic metastasis No
        symptomatic brain metastasis

        PATIENT CHARACTERISTICS: Age: 18 to 80 Performance status: WHO 0-2 Life expectancy: At
        least 3 months Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Hepatic: AST and
        ALT no greater than 3 times upper limit of normal (ULN) Alkaline phosphatase no greater
        than 5 times ULN Renal: Not specified Other: No bowel obstruction No other significant,
        uncontrolled underlying medical or psychiatric condition No serious active infection
        Neurologically stable No other prior malignancy except nonmelanomatous skin cancer or
        carcinoma in situ of the cervix No psychological, social, familial, or geographical
        condition that would preclude study Not pregnant or nursing Fertile patients must use
        effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
        Characteristics Endocrine therapy: Not specified Radiotherapy: At least 2 weeks since prior
        radiotherapy Surgery: At least 2 weeks since prior surgery Other: No other concurrent
        experimental drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Hebbar, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospital Universitaire Hop Huriez</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Drevon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Bernard</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospital Universitaire Hop Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Jean</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Meulan</name>
      <address>
        <city>Meulan</city>
        <zip>78250</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intercommunal Hospital</name>
      <address>
        <city>Montfermeil</city>
        <zip>93370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <zip>68051</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Hospital of Paris</name>
      <address>
        <city>Neuilly Sur Seine</city>
        <zip>F-92202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat-Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Gallien</name>
      <address>
        <city>Quincy Sous Senart</city>
        <zip>91480</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique De Courlancy</name>
      <address>
        <city>Reims</city>
        <zip>F-51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. Senlis</name>
      <address>
        <city>Senlis</city>
        <zip>60300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de l'Orangerie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2002</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2000</study_first_submitted>
  <study_first_submitted_qc>March 5, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2004</study_first_posted>
  <last_update_submitted>January 10, 2009</last_update_submitted>
  <last_update_submitted_qc>January 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2009</last_update_posted>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

